A Phase 1 Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients With Refractory or Relapsed Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2012
At a glance
- Drugs Imetelstat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.